Incidence of bleeding in patients on different anticoagulants and antiplatelet therapies undergoing thoracentesis.
Pleural Disease
Journal
BMJ open respiratory research
ISSN: 2052-4439
Titre abrégé: BMJ Open Respir Res
Pays: England
ID NLM: 101638061
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
13
01
2021
accepted:
13
04
2021
entrez:
20
7
2021
pubmed:
21
7
2021
medline:
25
11
2021
Statut:
ppublish
Résumé
Thoracentesis is one of the most commonly performed procedures in the inpatient setting. Although coagulation profile is usually evaluated prior to thoracentesis, bleeding is a rare complication, occurring in less than 1% of the cases. Several society guidelines recommend holding antiplatelet medications and anticoagulants prior to thoracentesis. Clinical practice guidelines also recommend correcting international normalised ratios of more than two and platelet counts <50 X10 This is a retrospective descriptive study that included 292 patients who underwent thoracentesis in the inpatient setting at Ascension St John Hospital in Detroit, Michigan, USA from 2016 to 2018. We identified patients who had uncorrected risk for bleeding and collected data about their demographics, comorbidities, use of antiplatelet or anticoagulants and procedural details including complications. We looked for any postprocedural bleeding events to study their relation to the already established bleeding risk. Two hundred and ninety-two thoracenteses were performed, 95.5% (n=279) were performed by interventional radiology. Majority of patients were at risk of bleeding 83% (n=242). No bleeding events occurred. Medications that were not held prior to thoracentesis included: clopidogrel 11% (n=32), novel anticoagulants 8.2% (n=24) and unfractionated heparin 50% (n=146). Use of ultrasound guidance decreased the amount of haemoglobin decline from 1 to 2 g/L (p=0.029). Seventeen patients suffered pneumothorax, eight of which required intervention. Our study suggests that performing thoracentesis without correction of underlying coagulopathy may be safe. This may prevent consequences of holding essential medications and reduce the amount of blood products administered to patients in need of thoracentesis.
Identifiants
pubmed: 34281915
pii: 8/1/e000874
doi: 10.1136/bmjresp-2021-000874
pmc: PMC8291320
pii:
doi:
Substances chimiques
Anticoagulants
0
Heparin
9005-49-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
AJR Am J Roentgenol. 2015 Aug;205(2):421-8
pubmed: 26204296
Transfusion. 2005 Sep;45(9):1413-25
pubmed: 16131373
J Am Coll Cardiol. 2005 Mar 15;45(6):954-9
pubmed: 15766835
Arch Bronconeumol. 2006 Jun;42(6):307-9
pubmed: 16827981
Eur Respir Rev. 2017 Jul 19;26(145):
pubmed: 28724563
Ann Am Thorac Soc. 2014 Jan;11(1):73-9
pubmed: 24102190
N Engl J Med. 2013 May 30;368(22):2113-24
pubmed: 23718166
J Vasc Interv Radiol. 2012 Jun;23(6):727-36
pubmed: 22513394
J Bronchology Interv Pulmonol. 2012 Oct;19(4):284-7
pubmed: 23207527
Chest. 2013 Aug;144(2):456-463
pubmed: 23493971
Arch Intern Med. 2010 Feb 22;170(4):332-9
pubmed: 20177035
Curr Opin Pulm Med. 2014 Jul;20(4):377-84
pubmed: 24852328
JAMA. 2005 May 4;293(17):2126-30
pubmed: 15870416
Respir Res. 2020 Oct 27;21(1):281
pubmed: 33109208
J Am Coll Cardiol. 2007 Aug 7;50(6):501-8
pubmed: 17678732
Jt Comm J Qual Patient Saf. 2016 Jan;42(1):34-40
pubmed: 26685932
J Formos Med Assoc. 2010 Aug;109(8):574-81
pubmed: 20708508